Consumables Leading The Pharmacogenomics Market Segment

By Author: Shreya
Total Articles: 19
Comment this article

Meticulous Research®—a leading global market research company, published a research report titled, ‘Pharmacogenomics Market by Offering (Instrument, Consumables, Software), Technology (PCR, Sequencing, Microarray), Application (Oncology, Mental Health, Cardiology, Neurology, Infectious Disease), End User (Hospitals, Academic) – Global Forecast to 2031.’
According to this latest publication from Meticulous Research®, the global Pharmacogenomics Market is set to reach nearly $19.5 billion by 2031, growing at a CAGR of 8.9% between 2024 and 2031. The market is being shaped by a few clear trends. One is the wider use of pharmacogenomic biomarkers in drug development. Another is the rise of personalized medicine and precision medicine, as treatments move away from the “one size fits all” approach. A larger elderly population and more cases of chronic illness are also adding pressure. Regulators such as the U.S. FDA and the EMA now recommend the use of pharmacogenomic data in research, which further supports growth. The one factor that slows progress is cost personalized medicines remain expensive. At the same ...
... time, new possibilities are opening. PGx testing (pharmacogenetic testing) is finding greater use in neurological disorders and cancer care. In oncology, the shift toward precision oncology and targeted cancer therapy is driving demand for companies like Invitae Pharmacogenomics and others working in pharmacology genomics. Better testing tools, stronger accuracy, and rising concern about adverse drug reactions are creating room for innovation. Still, barriers exist. Many patients and even healthcare providers have limited knowledge of pharmacogenetics and PGx testing. Awareness of how personalized medicine works is still low. Reimbursement policies for genetic testing and targeted therapy are weak in many regions. These challenges continue to limit the full potential of the Pharmacogenomics Market.
Key Players
The key players operating in the global pharmacogenomics market are F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), QIAGEN N.V. (Netherlands), and Pacific Biosciences of California, Inc. (U.S.).
Pharmacogenomics Market by Offering: Consumables, Instruments, and Software & Services
When looking at offerings, the Pharmacogenomics Market is divided into three parts: consumables, instruments, and software & services. Out of these, consumables are picking up the fastest growth and are expected to keep that lead through 2031. One reason is that chronic diseases are rising. Another is that labs need better kits and reagents for PGx testing and other pharmacogenetic testing methods. A lot of companies are working on new consumables. They want faster results and simpler workflows. Take QIAGEN N.V. as an example. In August 2022, the company launched the QIAseq UPXome RNA Library Kit and the QIAseq Targeted DNA Pro Panels. These products are designed to save time in cancer research labs. That matters for areas like precision oncology and targeted cancer therapy, where timing can be critical. This push for new consumables shows how central pharmacogenomic biomarkers are becoming. It also reflects how pharmacology genomics is shaping personalized medicine, precision medicine, and even broader targeted therapy approaches.
Pharmacogenomics Market Segmentation: PCR, Sequencing, Microarray, Mass Spectrometry & More
The Pharmacogenomics Market uses different technologies such as polymerase chain reaction (PCR), sequencing, microarray, mass spectrometry, and electrophoresis. Out of these, PCR is still the most common and is expected to hold the biggest share in 2024. The reasons are quite simple. PCR is accurate, sensitive, and does not need a large sample. It is also cheaper than some other options, which makes it popular in hospitals, labs, and research centres. Another reason is that companies keep bringing new PCR kits for PGx testing and trying to get approvals, which keeps the segment moving forward. PCR is used in many ways inside pharmacology genomics and personalized medicine. It helps with gene expression, cloning, sequencing, genotyping, mutagenesis, and methylation studies. Over time, it has improved a lot. The most common version now is quantitative PCR (qPCR), also called real-time PCR. qPCR is important in pharmacogenomics research because it can measure genetic variation and gene expression very precisely. This matters for drug response studies and for the growth of precision medicine, precision oncology, and targeted cancer therapy. With the support of pharmacogenomic biomarkers, PCR continues to play a central role in reducing side effects and improving treatment outcomes.
Rising Cancer Burden Drives Growth of Pharmacogenomics in Oncology
The pharmacogenomics market is used in many areas, like oncology, mental health, cardiology, neurological disorders, and infectious diseases. Out of these, oncology is the biggest in 2024. The reason is cancer is still common everywhere. Doctors need better ways to treat it. Pharmacogenomics makes this possible. It helps with personalized medicine and targeted therapy, where treatments match a person’s genes. In cancer care, that means fewer side effects and better results. Pharmacogenomic biomarkers are now used in precision oncology and targeted cancer therapy. More cancer cases also mean a stronger push for early detection and safer drugs. This is why PGx testing is growing fast. Companies like Invitae Pharmacogenomics are working on this space. Their tests lower the risk of bad drug reactions and guide doctors to choose the right drug. Because of all this, oncology is still the top segment in pharmacology genomics and pharmacogenetics.
Pharmacogenomics Market Growth Driven by Hospitals & Diagnostic Centers
Hospitals and diagnostic labs are expected to take the lead in the pharmacogenomics market in 2024. That is not surprising. These centres handle most of the testing, run a large share of clinical trials, and are often the first to adopt precision medicine. With more patients dealing with chronic illnesses, the demand for pharmacogenetic (PGx) testing is only moving upward. Private companies are also pushing this trend forward. Take Castle Biosciences, for example. In 2022, it bought Athlea Dx and its IDgenetix test, which helps physicians choose the right treatment for mental health conditions such as anxiety and depression. Deals like this show how hospitals and labs are becoming central to personalized medicine, targeted therapy, and precision oncology, backed by the growing use of pharmacogenomic biomarkers.
Regional Insights: Pharmacogenomics Market Share and Growth Outlook
When you look at the Pharmacogenomics Market by region, North America is still on top in 2024. The U.S. and Canada have more genetic testing programs in place newborn screening, cancer testing, etc. and a lot of the big PGx and personalized medicine companies are here. That mix keeps the region in the lead. Europe comes next. Countries like Germany, France, and the U.K. are pushing precision medicine and making more use of pharmacogenomic biomarkers in hospitals. Adoption is not uniform, but awareness is strong. Asia-Pacific is the fast riser. China, Japan, and India are putting more money into PGx testing and precision oncology. Hospitals are starting to use these tools more often, and patient awareness is catching up. Latin America plus the Middle East & Africa are smaller markets right now. Still, interest in targeted therapy and personalized medicine is growing slowly, so there’s room for expansion over time.
Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5366
Key questions answered in the report:
Which factors are driving the overall growth of the pharmacogenomics market?
What challenges slow down the adoption of pharmacogenomics globally?
How is personalized medicine shifting away from the “one-size-fits-all” approach?
What role does the aging population play in market expansion?
Why do high costs remain a major barrier for personalized medicine adoption?
How do weak reimbursement policies impact genetic testing uptake?
Which companies are the major players in the pharmacogenomics market?
What strategies are companies like QIAGEN, Illumina, and Invitae using to strengthen their positions?
What makes PCR a cost-effective and widely used option in PGx testing?
How is real-time PCR (qPCR) advancing pharmacogenomics research?
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research